Basket

0584811 - BTÚ 2025 RIV GB eng J - Journal Article
Malarikova, D. - Jorda, R. - Kupcová, K. - Senavova, J. - Dolníková, A. - Pokorná, E. - Kazantsev, D. - Nozickova, K. - Sovilj, Dana - Bellanger, C. - Chiron, D. - Anděra, Ladislav - Kryštof, V. - Strnad, Miroslav - Helman, K. - Klánová, M. - Trněný, M. - Havranek, O. - Klener, P.
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without iRB1/i deletion.
EXP HEMATOL ONCOL. Roč. 13, č. 1 (2024), č. článku 34. E-ISSN 2162-3619
Institutional support: RVO:86652036 ; RVO:61389030
Keywords : cdk4/6 * Cyclin-dependent kinase (CDK) inhibitors * Palbociclib * bcl2 * Venetoclax * rb1 * Mantle cell lymphoma (MCL)
OECD category: Oncology
Impact factor: 10.9, year: 2022
Method of publishing: Open access
https://ehoonline.biomedcentral.com/articles/10.1186/s40164-024-00499-2
Permanent Link: https://hdl.handle.net/11104/0353392